

French National Agency for Medicines and Health Products Safety

CERTIFICATE NUMBER: **19MPP100HFR01**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:

The manufacturer: **SIEGFRIED ST VULBAS SAS**

Site address: **Parc Industriel de la Plaine de l'Ain, 530 Allée de la Luye, SAINT VULBAS, 01150, France**

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2019-11-07** , it is considered that it complies with :

- The principles of GMP for active substances³ referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

27 MAI 2020

**COPIE CERTIFIÉE
CONFORME**





Part 2

Manufacture of active substance. Names of substances subject to inspection :

CYCLIZINE(en)

CYCLIZINE HYDROCHLORIDE(en)

TOFOGLIFLOZIN(en)

TROSPIMUM CHLORIDE(en)

ARTICAINE HYDROCHLORIDE(en)

BAMBUTEROL HYDROCHLORIDE(en)

EFAVIRENZ(en)

FERRIC CITRATE(en)

DAPAGLIFLOZIN(en)

APIXABAN(en)

ATAZANAVIR SULFATE(en)

FOSINOPRIL SODIUM(en)

LACOSAMIDE(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : CYCLIZINE

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.2 Manufacture of crude active substance

3.1.3 Salt formation / Purification steps :
Crystallization

3.5 General Finishing Steps

3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)

3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

Active Substance : CYCLIZINE HYDROCHLORIDE

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.2 Manufacture of crude active substance

3.1.3 Salt formation / Purification steps :
Crystallization

3.5 General Finishing Steps

3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)


3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

3.6 Quality Control Testing

**COPIE CERTIFIÉE
CONFORME**




27 MAI 2020



	3.6.1 Physical / Chemical testing
Active Substance : TOFOGLIFLOZIN	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : TROSPIMUM CHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : ARTICAINE HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : BAMBUTEROL HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :

COPIE CERTIFIÉE
CONFORME



27 MAI 2020




	Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : EFAVIRENZ	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : FERRIC CITRATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.3 Salt formation / Purification steps : Precipitation
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : DAPAGLIFLOZIN	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

**COPIE CERTIFIÉE
CONFORME**



27 MAI 2020



Active Substance : APIXABAN

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Active Substance : ATAZANAVIR SULFATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing


Active Substance : FOSINOPRIL SODIUM

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Active Substance : LACOSAMIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

COPIE CERTIFIÉE
CONFORME



27 MAI 2020



Clarifying remarks (for public users)

Signatory : Mrs Linda Gallais, head of starting materials inspection department --- The ANSM does not issue hard copies of good practices certificates

2020-01-27

Name and signature of the authorised person of the
Competent Authority of France

Confidential
French National Agency for Medicines and Health
Products Safety
Tel: *Confidential*
Fax: *Confidential*

27 MAI 2020



COPIE CERTIFIÉE
CONFORME

CHILI

APOSTILLE
(Convention de La Haye du 5 octobre 1961)

1. République française

Le présent acte public

2. a été signé par **Eric CHAUVINEAU**

3. agissant en qualité de **notaire associé**

4. est revêtu du sceau/timbre de son étude à
AMBERIEU-EN-BUGEY

Attesté

5. à **LYON**

6. le **10 Juin 2020**

7. par le Procureur Général près la Cour d'appel de Lyon

8. sous le n° **3656** (6 pages)

9. Sceau

10. Signature

Jean-François PISCIONE

"L'Apostille confirme seulement l'authenticité de la signature, du sceau ou timbre sur le document. Elle ne signifie pas que le contenu du document est correct ou que la République française approuve son contenu."

